IL23A and Crohn disease: As mentioned earlier, blockade of myeloid specific cytokines IL-1β, IL-12, and IL-23 have proven to be efficient therapies in multiple diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and systemic juvenile idiopathic arthritis.